This study shows that the approach of controlling Ras activity by promoting its proteosomal degradation via inhibition of the Wnt/β-catenin pathway can be an effective targeted therapeutic strategy for the treatment of KRAS-mutated NSCLC. This evidence concerns the gene KRAS and non-small cell lung carcinoma.